Diabetic polyneuropathy: progress in diagnostic strategy and novel target discovery, but stagnation in drug development.
Diabetic polyneuropathy (DPN), one of the most prevalent diabetic complications, asymptomatically progresses in the early stages of the disease. Although early diagnosis is critical since therapeutic intervention is often delayed, no consensus has been established for early diagnosis. However, fortunately, the recent development of objective quantitative tests that contribute to the diagnosis of DPN has been remarkable.